Journal issues > Issue 6, October 2024 > Concurrent chronic myeloid leukaemia and myelodysplastic/ myeloproliferative neoplasm with SF3B1 mutation and fulminant thrombocytosis

Concurrent chronic myeloid leukaemia and myelodysplastic/ myeloproliferative neoplasm with SF3B1 mutation and fulminant thrombocytosis

By: E. De Backer MD, K. Deiteren MD, A. De Vooght MD, S. Libbrecht MD, S. De Bruijn MD

SUMMARY

Myeloproliferative neoplasms (MPN) consist of a heterogeneous group of chronic hematological disorders currently classified according to their clinical, phenotypical, and genomic features. Co-existence of JAK2 V617F mutation and BCR::ABL1 fusion gene have been described earlier. However, the concomitant diagnosis of chronic myeloid leukaemia (CML) and myelodysplastic/myeloproliferative neoplasm overlap syndrome with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T) has not been reported before. We present a case of a 71-year-old female, known with a previous diagnosis of JAK2 V617F mutated MPN and subsequent diagnosis of BCR::ABL1-positive CML and MDS/MPN-SF3B1-T, developing fulminant thrombocytosis (5.481×10^9/L), necessitating thrombocytapheresis and making this case unique.

(BELG J HEMATOL 2024;15(6):238–45)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top